Summary Avacta Group Plc (Avacta) is a healthcare company that offers technology services. The company provides proprietary solutions to the life sciences and healthcare sector. It offers products such as optim and sensipod. Avacta has also developed UCB celltech, which is an analytical instrument. The company's sensipod is an in-clinical blood testing system that delivers ELISA tests. It provides intellectual property relating to an alternative to antibodies. The company's technology is engineered as an alternative to antibodies and aptamers. It caters to life science researchers. Avacta is headquartered in Wetherby, the UK. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Avacta Group Plc - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Avacta Group Plc Company Snapshot 6 Avacta Group Plc Company Overview 6 Avacta Group Plc Pipeline Products and Clinical Trials Overview 7 Avacta Group Plc - Pipeline Analysis Overview 9 Key Facts 9 Avacta Group Plc - Major Products and Services 10 Avacta Group Plc Pipeline Products by Development Stage 11 Avacta Group Plc Pipeline Products Overview 13 Depression Test 13 Depression Test Product Overview 13 Diagnostic Assay - Alzheimer's Disease 14 Diagnostic Assay - Alzheimer's Disease Product Overview 14 Diagnostic Test - ADHD 15 Diagnostic Test - ADHD Product Overview 15 Diagnostic Test - Bipolar Disorder 16 Diagnostic Test - Bipolar Disorder Product Overview 16 Portable Pathogen Detection System 17 Portable Pathogen Detection System Product Overview 17 Schizophrenia Response Test 18 Schizophrenia Response Test Product Overview 18 Schizophrenia Side Effects Test 19 Schizophrenia Side Effects Test Product Overview 19 Avacta Group Plc - Key Competitors 20 Avacta Group Plc - Key Employees 21 Avacta Group Plc - Locations And Subsidiaries 22 Head Office 22 Other Locations & Subsidiaries 22 Recent Developments 23 Avacta Group Plc, Recent Developments 23 Jun 22, 2016: Avacta Rapidly Generates Affimer Binders for Zika Virus Diagnostics 23 Apr 25, 2016: Avacta Group: Interim Results for the Period Ended 31 January 2016 23 Apr 19, 2016: Affimer Therapeutic Platform Development Milestone Achieved 24 Jan 25, 2016: Avacta Appoints Philippe Cotrel as Chief Commercial Officer 25 Jul 07, 2015: Avacta Group announces Board Change 25 Oct 16, 2014: Avacta Group Provides Year end Results 25 Sep 30, 2014: Avacta Group Announces Affimer On-line Catalogue Launch 27 Jun 02, 2014: Avacta secures funding award to develop Affimers for therapeutic out-licensing 27 Apr 23, 2014: Avacta Group Announces Interim Results 28 Mar 20, 2014: Affimers Announces Technical and Commercial Update 29 Appendix 30 Methodology 30 About GlobalData 30 Contact Us 30 Disclaimer 30
List of Tables
Avacta Group Plc Pipeline Products and Clinical Trials Overview 7 Avacta Group Plc Pipeline Products by Equipment Type 7 Avacta Group Plc Pipeline Products by Indication 8 Avacta Group Plc, Key Facts 9 Avacta Group Plc, Major Products and Services 10 Avacta Group Plc Number of Pipeline Products by Development Stage 11 Avacta Group Plc Pipeline Products Summary by Development Stage 12 Depression Test - Product Status 13 Depression Test - Product Description 13 Diagnostic Assay - Alzheimer's Disease - Product Status 14 Diagnostic Assay - Alzheimer's Disease - Product Description 14 Diagnostic Test - ADHD - Product Status 15 Diagnostic Test - ADHD - Product Description 15 Diagnostic Test - Bipolar Disorder - Product Status 16 Diagnostic Test - Bipolar Disorder - Product Description 16 Portable Pathogen Detection System - Product Status 17 Portable Pathogen Detection System - Product Description 17 Schizophrenia Response Test - Product Status 18 Schizophrenia Response Test - Product Description 18 Schizophrenia Side Effects Test - Product Status 19 Schizophrenia Side Effects Test - Product Description 19 Avacta Group Plc, Key Employees 21 Avacta Group Plc, Subsidiaries 22
List of Figures
Avacta Group Plc Pipeline Products by Equipment Type 8 Avacta Group Plc Pipeline Products by Development Stage 11
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.